Skip to content

INNOVATIVE CELLULAR THERAPIES TO TREAT SOLID TUMORS

Revolutionizing Solid Tumor Treatment by Turning Tumor
Defenses Into CAR T Cell Strengths

INNOVATIVE CELLULAR THERAPIES TO
TREAT SOLID TUMORS

Revolutionizing Solid Tumor Treatment by Turning Tumor Defenses Into
CAR T Cell Strengths.

Who We Are

At Simurx, we are driven by a deep commitment to scientific excellence and an unwavering determination to enhance outcomes for cancer patients. Our team of scientists has pioneered the CTSR platform, a groundbreaking technology that harnesses the immunosuppressive properties of the tumor microenvironment to significantly improve the efficacy of cell therapies. This innovation is protected by a comprehensive patent portfolio.

Our multidisciplinary and integrative approach to product development ensures that we remain at the forefront of cancer therapy innovation. With our cutting-edge technology, Simurx is uniquely positioned to deliver a wide range of multifunctional CAR T-cell therapies, offering new hope to cancer patients around the world.

our-platform-358x258

Our Platform

Our patented chimeric TGFβ-signaling receptor (CTSR) platform promotes survival in a hostile tumor environment and can be modularly combined with other engineered cell therapies

the-science-358x258

The Science

The CTSR platform soaks up immunosuppressive molecules from the tumor microenvironment while promoting CAR-T proliferation and immune activation.

our-pipline-358x258

Our Pipeline

The modular design and inherent flexibility of the CTSR platform allow its incorporation into a multitude cellular therapies

Latest News

 

Corporate HQ

2265 E Foothill Blvd
Pasadena, California 91107
United States

Contact

Phone: (310) 629-0476
Fax: (310) 361-6903